Stay updated with breaking news from Biodesix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biodesix (NASDAQ:BDSX – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Biodesix Inc. is a data-driven diagnostic solutions company. It offers blood-based tests across the lung cancer continuum of care. The […]
Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively Full-Scale Launch of GeneStrat... | March 14, 2022
Geode Capital Management LLC boosted its position in shares of Biodesix, Inc. (NASDAQ:BDSX – Get Rating) by 3.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 151,023 shares of the company’s stock after acquiring an additional 5,064 shares during the period. Geode Capital […]
BOULDER, Colo.--(BUSINESS WIRE)--$BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the BTIG MedTech, Digital Health, Life Science &...